Bentiromide
(Synonyms: 苯替酪胺) 目录号 : GC35491
Bentiromide is a peptide which is broken down in the pancreas by chymotrypsin. The bentiromide test is a test of pancreatic exocrine function.
Cas No.:37106-97-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Bentiromide is a peptide which is broken down in the pancreas by chymotrypsin. The bentiromide test is a test of pancreatic exocrine function.
| Cas No. | 37106-97-1 | SDF | |
| 别名 | 苯替酪胺 | ||
| Canonical SMILES | O=C(O)C1=CC=C(NC([C@@H](NC(C2=CC=CC=C2)=O)CC3=CC=C(O)C=C3)=O)C=C1 | ||
| 分子式 | C23H20N2O5 | 分子量 | 404.42 |
| 溶解度 | DMSO: ≥ 250 mg/mL (618.17 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4727 mL | 12.3634 mL | 24.7268 mL |
| 5 mM | 0.4945 mL | 2.4727 mL | 4.9454 mL |
| 10 mM | 0.2473 mL | 1.2363 mL | 2.4727 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
The Bentiromide test for pancreatic exocrine insufficiency
Pharmacotherapy 1984 Mar-Apr;4(2):74-80.PMID:6371722DOI:10.1002/j.1875-9114.1984.tb03322.x.
The Bentiromide test, a test of pancreatic exocrine function, has recently been approved for clinical use by the Food and Drug Administration. The test has been studied in adult patients with chronic pancreatic disease and in children with cystic fibrosis. The 500-mg dose and 6-hour urine collection period appear optimal for separating patients with chronic pancreatic disease from control subjects. Side effects with the 500-mg dose are virtually nonexistent. This simply performed outpatient test of chymotrypsin function appears to be an excellent means of confirming the diagnosis of pancreatic exocrine insufficiency.
The Bentiromide test using plasma p-aminobenzoic acid for diagnosing pancreatic insufficiency in young children. The effect of two different doses and a liquid meal
Gastroenterology 1991 Jul;101(1):207-13.PMID:2044909DOI:10.1016/0016-5085(91)90479-5.
The Bentiromide test was evaluated using plasma p-aminobenzoic acid as an indirect test of pancreatic insufficiency in young children between 2 months and 4 years of age. To determine the optimal test method, the following were examined: (a) the best dose of Bentiromide (15 mg/kg or 30 mg/kg); (b) the optimal sampling time for plasma p-aminobenzoic acid; and (c) the effect of coadministration of a liquid meal. Sixty-nine children 91.6 +/- 1.0 years) were studied, including 34 controls with normal fat absorption and 35 patients (34 with cystic fibrosis) with fat maldigestion due to pancreatic insufficiency. Control and pancreatic insufficient subjects were studied in three age-matched groups: (a) low-dose Bentiromide (15 mg/kg) with clear fluids; (b) high-dose Bentiromide (30 mg/kg) with clear fluids; and (c) high-dose Bentiromide with a liquid meal. Plasma p-aminobenzoic acid was determined at 0, 30, 60, and 90 minutes then hourly for 6 hours. The dose effect of Bentiromide with clear liquids was evaluated. High-dose Bentiromide best discriminated control and pancreatic insufficient subjects, due to a higher peak plasma p-aminobenzoic acid level in controls, but poor sensitivity and specificity remained. High-dose Bentiromide with a liquid meal produced a delayed increase in plasma p-aminobenzoic acid in the control subjects probably caused by retarded gastric emptying. However, in the pancreatic insufficient subjects, use of a liquid meal resulted in significantly lower plasma p-aminobenzoic acid levels at all time points; plasma p-aminobenzoic acid at 2 and 3 hours completely discriminated between control and pancreatic insufficient patients. Evaluation of the data by area under the time-concentration curve failed to improve test results. In conclusion, the Bentiromide test is a simple, clinically useful means of detecting pancreatic insufficiency in young children, but a higher dose administered with a liquid meal is recommended.
Further evaluation of Bentiromide in the diagnosis of canine exocrine pancreatic insufficiency
Cornell Vet 1985 Jul;75(3):426-40.PMID:3874751doi
The primary objective of this study was to evaluate the accuracy of the Bentiromide test in differentiating between dogs with exocrine pancreatic insufficiency (EPI) and those with primary intestinal disease (PID). A secondary objective was to correlate the results of the commonly used diagnostic techniques with the results of the Bentiromide test. This test consists of the oral administration of a synthetic peptide that is cleaved only by chymotrypsin. A subsequent rise in the plasma concentration of p-aminobenzoic acid (PABA) indicates the degree of cleavage, providing an in vivo assessment of chymotrypsin activity. Fourteen dogs with EPI and five dogs with PID were categorized on the basis of clinical signs, laboratory evaluations, and histologic examination of intestinal biopsies. Six normal dogs served as controls. The Bentiromide test clearly identified the dogs with EPI and distinguished them from the dogs with PID and the control dogs. The results of the Bentiromide test correlated well with the results of the clinical and laboratory evaluations. On the basis of these observations and conclusions, recommendations for the pragmatic application of the Bentiromide test are offered.
Bentiromide test for assessing pancreatic dysfunction using analysis of para-aminobenzoic acid in plasma and urine. Studies in cystic fibrosis and Shwachman's syndrome
Gastroenterology 1985 Sep;89(3):596-604.PMID:3874804DOI:10.1016/0016-5085(85)90456-1.
We evaluated the Bentiromide test by analyzing para-aminobenzoic acid (PABA) in plasma and urine (a) for the identification of patients with complete pancreatic insufficiency and (b) as an alternative to the secretin-cholecystokinin test. Nine control subjects, 18 patients with cystic fibrosis, and 4 patients with Shwachman's syndrome were studied. Based upon the secretin-cholecystokinin test, pancreatic function was judged to be less than 0.1% of normal in 7 patients with cystic fibrosis and malabsorption and between 0.7% and 90% of control values in 11 patients with cystic fibrosis and 4 patients with Shwachman's syndrome without malabsorption. The Bentiromide test was performed in two stages: first with Bentiromide alone, then with equimolar free PABA. After ingestion of free PABA, the plasma profile and urinary excretion of PABA were comparable in controls, patients with cystic fibrosis, and patients with Shwachman's syndrome. Thirty minutes after oral Bentiromide, plasma PABA values in patients with and without malabsorption were significantly lower than in the control group. From 60 to 180 min after ingestion, plasma PABA levels in patients without malabsorption were no different from controls; whereas levels in patients with malabsorption were significantly lower than in controls and in those without malabsorption, reaching the highest significance at 90 min. Similar results were obtained when the urinary excretion of PABA was considered. Only the 90-min plasma test reliably detected cystic fibrosis patients with steatorrhea, however. Duodenal colipase output was highly correlated with both the 90-min plasma test and the urinary excretion of PABA, with similar results for lipase and trypsin output. Reliable detection of pancreatic dysfunction, nevertheless, was not obtained even with the plasma test, in cystic fibrosis patients with greater than 5%-10% of the mean normal enzyme output. In patients with Shwachman's syndrome, none of whom had malabsorption, the plasma and urinary test failed to detect pancreatic dysfunction even with enzyme output as low as 1% of normal.
Bentiromide as a test of exocrine pancreatic function in adult patients with pancreatic exocrine insufficiency. Determination of appropriate dose and urinary collection interval
Gastroenterology 1983 Sep;85(3):565-9.PMID:6603385doi
A dose-ranging crossover study of orally administered Bentiromide was conducted in 47 patients with chronic pancreatic disease and 61 healthy volunteers. Four doses (100 mg, 500 mg, 1 g, and 5 g) and postdosing urine collection periods (0-3, 0-6, 0-12, and 0-24 h) were studied. Of these, the 500-mg dose and 0-6-h urine collection period afforded maximal separation of urinary arylamine excretion rates between the two populations. At this dose and collection period, the lower limit of normal (mean - 2 SD) for the control group was 57%; none of the healthy volunteers had 6-h arylamine excretion rates less than 50%. The agent was well tolerated except at the 5-g dose level, where nausea, vomiting, and diarrhea were common. Bentiromide appears to be a useful agent in the assessment of exocrine pancreatic function.